Prostate Cancer
Conditions
Keywords
Prostate Cancer, Patient Derived Xenograft, CRPC
Brief summary
The investigators intend to use the Second-generation sequencing（NGS）and MiniPDX drug sensitivity models to guide the treatment decision-making for patients who were resistant to abiraterone, enzalutamide or other new second-generation anti-androgenic drugs. In order to develop precise personalized treatment plans for patients and extent their lifetimes.
Detailed description
Most patients with metastatic prostate cancer are effective in endocrine therapy at the beginning, but after a median survival of 12 to 18 months, almost all patients develop castration-resistant prostate cancer (CRPC). Since the pathogenesis of CRPC is still unknown, the clinical lack of precise treatment for the cause is a difficult and hot topic in current research and treatment. Mini patient derived xenograft (MiniPDX) is a drug sensitivity test model established by transplanting primary human tumor cells into immunodeficient mice by special methods. This efficient drug sensitivity test can provide sensitivities of single drug or drug combination in order to screen out the optimal individualized regimens for each patient. The investigators intend to use the Second-generation sequencing（NGS）and MiniPDX drug sensitivity models to guide the treatment decision-making for patients who were resistant with abiraterone, enzalutamide or other new second-generation anti-androgenic drugs. This project is to develop precise personalized treatment plans for patients and extent their lifetimes.
Interventions
OTHERMiniPDX Group
Mini patient derived xenograft (MiniPDX) is a drug sensitivity test model established by transplanting primary human tumor cells into immunodeficient mice by special methods. This test can provide sensitivities of single drug or drug combination within 7 days to screen out the optimal individualized regimens for each patient.
Sponsors
Tianjin Medical University Second Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient can provide detailed clinical baseline information including: name, age, gender, pathology, past treatment, etc.; 2. Male, age ≥ 18 years old; 3. ECOG score 0\ 2 points; 4. Patient must be able to provide tissue samples for the drug sensitive test; 5. No treatment history with PI3K inhibitors, AKT inhibitors or mTOR inhibitors; 6. Estimated lifetime is ≥ 3 months; 7. Histological or cytologically determined prostate adenocarcinoma, excluding neuroendocrine differentiation, signet ring cell carcinoma and small cell carcinoma; 8. Patient is at a castration level and the testosterone level is lower than \<50 ng/dL or 1.7 nmol/L; 9. Received abiraterone or enzalutamide and other new second-generation anti-androgenic drugs and have disease progression. Disease progression is defined by PCWG3 :The progression of disease in PCWG3 is defined as satisfying one of the following: according to the increase in PSA levels, there must be three consecutive increases in PSA at least one week apart, and the minimum value is greater than or equal to 5.0 ng/ml; disease progression as assessed by RECIST 1.1, considering PSA levels or not; PCWG3 defines bone disease progression, which is bone scan found 2 or more new lesions; 10. Evidence of distant metastatic disease (such as bone scans and CT/MRI results), imaging data that can be used to assess the condition before and after treatment, or imaging experience provided by three imaging hospitals with experience in three hospitals. Test reports and oncology indicators include PSA values; 11. The patient can tolerate the primary physician to perform the puncture operation, after receiving the informed consent from the patient and the family members; 12. The follow-up period must be at least greater than 2 months; 13. Be able to follow the research and follow-up procedures to provide real and effective information; 14. The patient or his legal guardian understands the test procedure and content and voluntarily signs the printed informed consent form.
Exclusion criteria
1. Cognitive ability and psychological abnormalities 2. ECOG score 3-4 points or blood biochemical examination indicates that the patient is not suitable for continuing chemotherapy or chemotherapy has been postponed 3. Can not provide enough tumor puncture tissue, not enough tumor cells for subsequent experiments; 4. Patient who is unwilling to receive follow-up treatment after the Mini PDX model drug sensitivity test; 5. The investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of this study (for administrative reasons or other reasons).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 12 months | The ratio of number of participants with evidence of a confirmed complete response (CR) or partial response (PR) to all participants is objective response rate (ORR) by using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 to evaluate. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 12 months | Progression-free survival (PFS) is defined as the time from the date of the first administration of patients medication plan based on MiniPDX drug sensitivity test to the date of the first documentation of disease progression or death due to any cause, whichever comes first, censored at the last date at which the participant was determined to be progression-free. |
| OS | 12 months | Overall survival is defined as time from initiation to death of any cause. |
| ADR | Up to 30 days of last study treatment. | Adverse Drug Reaction：Adverse events determined according to CTCAE (version 4.03) and attribution to study treatment. |
| Clinical Consistency | Up to 2 months of last study treatment. | Overall clinical consistency（accuracy） as assessed by evaluating Response Evaluation Criteria In Solid Tumors (RECIST) criteria in patient tumor and correlating to tumor regression in Mini-PDX model for same drug treatment. |
Countries
China
Contacts
Primary ContactHaitao Wang, Ph.D
Outcome results
None listed